๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Inspire Medical Systems, Inc. (INSP)
NYSE: INSP ยท Real-Time Price ยท USD
56.28
-1.83 (-3.15%)
Nov 19, 2026, 4:00 PM EST - Market closed
โ† View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 10, 2026

Summary

Inspire outlined a path back to low-single-digit revenue growth in 2027, supported by improved reimbursement, rising ASC use and growth reinvestment. Inspire V clinical performance and future automation and remote-care tools remain key priorities.

Jon Block
Analyst, Stifel

Jon Block with Stifel, and I am happy to introduce the team from Inspire Medical. Tim Herbert, Chairman and CEO, Matt Osberg, CFO. We are going to do predominantly Q&A, but I just spoke to Tim. We are going to kick things off with a couple slides. I will hand the floor over to Tim. We will go over a couple slides, and then we will jump into Q&A from there.

Tim Herbert
CEO, Inspire Medical

Very good, Jon. Thank you very much for hosting us again this year.

Jon Block
Analyst, Stifel

Yeah.

Tim Herbert
CEO, Inspire Medical

We really enjoy this conference and enjoy having all the meetings that we have had with everybody today. It has been very informative. I just have to click on that. Or is he driving it?

Jon Block
Analyst, Stifel

I think we are trying to rectify the-

Tim Herbert
CEO, Inspire Medical

We're trying to sign up for a free trial. What if we learn more?

Jon Block
Analyst, Stifel

How are we doing back there on the slides?

Speaker 3

Working on it.

Jon Block
Analyst, Stifel

Okay. Yeah.

Tim Herbert
CEO, Inspire Medical

There we go. Go ahead. Okay, advance the slide again, if you will. One more.

Jon Block
Analyst, Stifel

There we go.

Tim Herbert
CEO, Inspire Medical

There we go. Quickly, just a quick overview. We really have an under-penetrated market right now, and I know we've had challenges over the last two years in continuing to grow our adoption, but we've always continued to focus on the clinical evidence. We have over 400 publications and more really important publications forthcoming. We're up to 1,300 employees, and most recently on the bottom, we just announced we've crossed over 150,000 patients have received Inspire therapy. What's so important to the team at Inspire and all the employees and the healthcare providers, it's all about clinical outcomes. With clinical outcomes, we can push the adoption as fast as we want, as long as we never give up on the patients. What's so unique about hypoglossal nerve stimulation is you need to identify when the patient inhales, because that's when the airway is susceptible to collapse.

We have a sensing capability, and so when the patient inhales, that's when we provide stimulation to the hypoglossal nerve to maintain an open airway. Now, what we've done with Inspire V, our fifth-generation device, we've taken a sensor that used to be placed between the intercostal muscles in a patient's chest, and we relocated that using an accelerometer that is now inside the neurostimulator, inside the body of the patient. Same technology that you see with cardiac pacemakers when we do rate-responsive pacing. As the patient goes jogging, it measures its respiratory rate and paces faster. We can use that same technology to measure respiration. What we found is it's a much more stable environment. You see how we measure this called inspiratory overlap, and what percent of the inspiratory cycle do we provide stimulation to maintain an open airway.

You can see we've improved that from 79% all the way to 87% with Inspire V. That translates into reductions in the severity of sleep, specifically in this case, the apnea-hypopnea index. The data that you see here is from a clinical study that was run in Singapore and will be published in the very near future. Couple key catalysts and updates that I'm sure Jon will have several questions on. This year has all been about reimbursement. We've had challenges with transitioning to Inspire V and what code to be able to use. When we went back to the code 64568 that everybody has heard us talk about so frequently during the year, there were challenges using that code and the reimbursement, so we needed to develop a new code as we progressed into 2026.

We were solving that with three steps, near term, medium term, and long term. The near term was there's temporary codes in place that centers can use to bill for an Inspire V. Those codes are in place. They've been educated with centers, and centers now know what code they need to use to be able to bill an Inspire V. Midterm is we want to improve the reimbursement at facilities. That came through last Thursday. Our earnings call was last Monday. Since then, last Thursday, we received the data that the OPPS or the reimbursement to the facilities for Inspire went up significantly. In fact, hospital reimbursement went up 11%, and reimbursement in the ambulatory surgical center went up 13.5%. That's really significant as we move forward. Of course, long term is a brand new CPT Category I code that was recently awarded.

In fact, we're right in the process right now for that code being valued, and that code will take effect January 1st, 2028. I already mentioned the Inspire V and the clinical data that we had. This was recently presented at the ENT conferences. There's two of them, the AAO and the ISSS meeting. Project Horizon, Matt Osberg will talk a little bit more about this, but as we continue to grow, we took the opportunity to look for efficiencies in our organization. We identified $30 million of efficiencies that we can reallocate towards growth, and we'll let Matt Osberg talk more about that. We're going to keep working on expanding our clinical evidence. It's about Inspire V performance that I mentioned. Talk about the physiologic disease impact. What's more important, it's not just about AHI, apnea-hypopnea index. It's about that term you see there, hypoxic burden.

That's the challenge that the body, it's the stress the body is under during a night of sleep with apneic events with the oxygen desaturating, and that has direct correlation with cardiovascular health and systemic outcomes. Finally, what we can do with this is work more so with patient identification and access to care. Quite a bit more moving forward on that. Let me hand it off to Matt for a summary of some financials.

Matt Osberg
CFO, Inspire Medical

Yep. Good afternoon, everyone. Thanks, Jon, for hosting. A quick summary of our 3Q highlights. As Tim said, we just had our call last week. We delivered results top and bottom line ahead of expectations. Although we were declining year-over-year, we importantly wanted to step up our revenue run rate from the second quarter to the third quarter. We were able to achieve that. We have a really strong gross margin for the company, 86%. We were able to expand that year-over-year, and that gives us a lot of ability to drive stronger operating margins as we continue to grow the top line. We have had a great year of cash flow. We have been able to improve cash flow year-over-year, even in a depressed top line situation.

The company has no debt, and we can continue to use our strong balance sheet and our cash positions to invest in growth. From an outlook perspective, for 2026, we narrowed the ranges top and bottom line for outlook for the year, and we did introduce a 2027 revenue outlook of low single-digit growth. As we have been talking about returning to growth in 2027, we wanted to start creating a picture of what that would look like for us as we get into next year. Tim mentioned Project Horizon. This is something that we announced in our second quarter, we executed on in our third quarter. It is really about utilizing some capacity in our organization where we had grown so much as an organization, we were able to look for efficiencies in our organizational structure and then rededicate some of those costs to high revenue-generating activities.

Some of that we started reinvesting in the third quarter. Some of it we will invest in the fourth quarter, and we have some more opportunity to invest as we go through our budgeting cycle and start to choose some initiatives for 2027. I will drop it over to Tim to wrap up.

Tim Herbert
CEO, Inspire Medical

Well, again, just quickly and then we will go to Jon-

Jon Block
Analyst, Stifel

Yeah

Tim Herbert
CEO, Inspire Medical

and for some Q&A. But really enhanced code and clarity in 2026 and 2027, and that really has us in the ability to get back to our game, which the team and the field are very excited about. Then, of course, we have the new code coming as we enter 2028. We are going to really focus on physician experience and patient outcomes, which is so important, and really start continuing to publish our new clinical evidence showing the cardiovascular benefits of long-term use of Inspire therapy. So with that, Jon, thanks for giving us a chance to kind of jump through some of those.

Jon Block
Analyst, Stifel

All good.

Tim Herbert
CEO, Inspire Medical

But let's hand it off to you and-

Jon Block
Analyst, Stifel

Good. After some questions?

Tim Herbert
CEO, Inspire Medical

Yeah, I'm sure you got some more detail you want to-

Jon Block
Analyst, Stifel

Just a couple pages. That's it.

Tim Herbert
CEO, Inspire Medical

peel the onion a little bit.

Jon Block
Analyst, Stifel

I'll start with reimbursement.

Tim Herbert
CEO, Inspire Medical

Yeah.

Jon Block
Analyst, Stifel

Obviously a hot topic. I will try to go 2027 and then 2028. 2027 reimbursement, Tim, you mentioned, good news out last week, 11% increase at the hospital, 13% at the ASC. It is one of the bigger increases in years that I can remember from a facility standpoint. What does this mean for Inspire? In other words, does this translate into, call it maybe more pricing power, or is it just sort of giving some of these facilities a bigger, greater incentive to increase their utilization?

Tim Herbert
CEO, Inspire Medical

Well, I think we are going to look at all aspects of that. When we put that in perspective, the increase is based on the national average Medicare payment, and those payments are geographically adjusted. When you go to the southern where the labor rates may be a little bit less, they get less Medicare reimbursement. There was a point in time where almost 40% of our procedures could not do Medicare because it puts them in a loss situation. Now with this increase, that really helps out. That gets the majority of the ASCs in the United States in a profitable situation where they can certainly offer Inspire therapy. We think that is really important. We believe, especially with Inspire V, the technology lends itself to really moving to an ASC.

I assume you have another question on that, so we will not go too far into that pathway yet. But we are going to look at that. As we put our detailed annual operating plan together on what it is, we will look at, do we maintain our common pricing point? Do we change that price point at this point? So a little early to think through this because these numbers just came out Thursday. We are highly encouraged by not only the increase in the hospital, but the way in which they calculated the discount to the ambulatory surgical centers from the hospital, and the result being the ASCs actually going up 13.5% is really a distinct opportunity. We have already seen a trend of procedures migrating more so to ASCs, and this is certainly one more data point that was going to continue to support that.

Jon Block
Analyst, Stifel

I remember when, a couple years ago when you started pushing into ASCs, you were hoping to really have that ramp.

Maybe just level set us. Where are you in terms of percent of procedures done at the ASC, and then how do we think about that progressing over the next one to two years with hopefully reimbursement a little bit more favorable there.

Tim Herbert
CEO, Inspire Medical

Sure. I think that a couple years ago, we looked at that and said, "It's time to start moving this to the ASCs," especially because we knew Inspire V was on the horizon. Once we launched Inspire V, of course, we unfortunately spent this year focused on coding and getting clarification on what the proper use of the code is. But the ASCs have rebound quite quickly with the new coding. As an example, in the third quarter, 25% of our surgical procedures were performed in an ambulatory surgical center. That's up from just a year ago when it was about 18%. That's a significant change. When we're looking at high single digits year- over- year down, yet we're seeing a positive impact in ASCs. That's a really good signal moving forward. That's where we want to be able to move this procedure.

Now that we have this in a position where physicians can leverage that, we're going to continue to push that quite harder. We believe we can get to a point where someday we'll be over half our procedures will be done in an ambulatory surgical center.

Jon Block
Analyst, Stifel

Okay. One more on 2027 reimbursement. Matt, as you mentioned, on your earnings call, you gave the low single-digit revenue growth for 2027. Sort of an early look, you did that on Monday. These codes come out Thursday. What did you embed in the guidance when we think about the anticipated increase that you saw? Does this give you a little bit of wiggle room when we think about the guidance?

Matt Osberg
CFO, Inspire Medical

Yes, we factored in that there is typically nominal increases, and that is what we expected when we gave the low single-digit guide. This gives some tailwind to that, and it is exciting opportunity for us to start doing some of the ASC strategies that Tim mentioned. We are looking at it for us as a tailwind and another reason that we think we can return to growth in 2027.

Jon Block
Analyst, Stifel

Okay. So, 2027 reimbursement I hit on. How about 2028?

Tim Herbert
CEO, Inspire Medical

That is a long ways away.

Jon Block
Analyst, Stifel

Yes, it is a long ways away, but as you know, you have to start working at it.

Tim Herbert
CEO, Inspire Medical

You do

Jon Block
Analyst, Stifel

Far in advance. The new code's in place. It's going to be for you guys and LivaNova, not Nyxoah. We recently heard the survey went out, the RUC survey went out. I think it was like late October. The process has started. Help us with the data points going forward. Where do we go from November 2026 until what? Do we hear anything until the prelims out in July of next year?

Tim Herbert
CEO, Inspire Medical

Sure. Once the code is accepted by the American Medical Association CPT committee, it then gets sent over to the RUC committee, who assigns it to a society to conduct a survey on the amount of work it takes to do that procedure. In our case, it was sent to the AAO-HNSF, the American Academy of Otolaryngology, who then sent that survey out to its membership. What's unique about doing the survey today as it was several years ago when we first did the 64582 code, there's just so many more surgeons who are trained on the procedure, over 1,500. So when they do the survey, they can get a greater volume of respondents, and by getting a greater volume, it gives a much more accurate picture with a tighter standard deviation.

I think the value that this will create in the eventual reimbursement or the RVUs, if you will, that ENTs will receive will be a much more accurate and truly reflect the procedure because there's such experienced surgeons out there. The survey is closed, and the AAO-HNSF is collecting all that information, and then they will go present that to the AMA RUC committee, and I think that'll happen early next year. That data will then be presented to CMS. I'm seeing if I can get a couple more acronyms in here.

Jon Block
Analyst, Stifel

Oof.

Tim Herbert
CEO, Inspire Medical

CMS will continue to review that, and the proposed rules will come out in July, just like the normal OPPS.

Jon Block
Analyst, Stifel

That is really the first look we get of it. Do you get anything before then or no?

Tim Herbert
CEO, Inspire Medical

I think the RUC and the AAO-HNSF will work in regards to the data itself to calculate the hours and ideally propose what RVUs, relative value units, that they would like CMS to pick up. I think the first time really publicly you see something formal or tangible is July.

Jon Block
Analyst, Stifel

July 27th.

Tim Herbert
CEO, Inspire Medical

That is the proposed, then of course it goes through comment period, then the final rule, just like the OPPS last week, will come out in November.

Jon Block
Analyst, Stifel

Okay. For that pro fee, Tim, I mean, are we thinking the time to complete the procedure? I think there are also other variables, right? Like in-office support, malpractice. Is the thought like the other two variables that I mentioned, those are static, those really shouldn't change. Maybe time comes down a little bit because of Inspire V efficiency, we will see. If we think about the other variables not changing, does that go into the calculus that maybe there is not a big movement on the pro fee for Inspire V?

Tim Herbert
CEO, Inspire Medical

Well, I think they will look at what data was submitted with the 64582 several years ago, from the middle bucket, the office support side, as long as collecting the data on the amount of work it takes to implant or perform the procedure itself. They will go back and reevaluate that and work with the RUC. It is unsure if it is going to remain static. That is something that the AAO-HNSF has to work with the RUC committee and propose that to CMS. The key to the code is there is a lot of experience with Inspire V procedures. So, like over 10,000 procedures last year and tens of thousands again this year. So there is a lot of experience for CMS to be able to do a read-across, if you will. But they did conduct a formal survey, which I think is really good.

Again, just highlighting if we can get a significant number of respondents, that gives a much more accurate measure. But I do not know if we are looking for anything earth-shattering one way or the other.

Jon Block
Analyst, Stifel

Okay. Last one, sorry, then we will move on. Should anything happen on the facility side of things, or is that more straightforward?

Tim Herbert
CEO, Inspire Medical

Well, again, I think there is enough experience with Inspire V, both with 64568, 64582, as well as the new C code that was issued by CMS earlier this year, that they all map to that level 5 ambulatory payment classification, or APC. That is the same reimbursement that just went up last Thursday.

Jon Block
Analyst, Stifel

Okay.

Tim Herbert
CEO, Inspire Medical

I think you can see a read-across where it will map to the same facility reimbursement.

Jon Block
Analyst, Stifel

Okay. I am going to move on to a different topic, and then Matt will circle back on guidance. In terms of new topic, coding and billing.

Tim Herbert
CEO, Inspire Medical

Coding

Jon Block
Analyst, Stifel

The code's moving around, then you go over to the C- codes. You had to go back out to a lot of your facilities, roughly 1,600 at last count, and educate them, right? Here's the process, here's how you do the procedure, here's how you bill for the procedure, pardon me. Where are you with that process? Obviously, you prioritized your high-volume centers first, but maybe walk us through where you are amongst the 1,600, or even more specifically, amongst some of the high-volume centers.

Tim Herbert
CEO, Inspire Medical

I think the information's available to all centers, and I believe the great majority of the centers know how to bill an Inspire V procedure today. The key is making sure that once they bill it, that they can audit it to make sure that they get the proper payment. What hasn't changed in this whole process is coverage, either from a commercial, Medicare Advantage, or the MACs. The coverage has remained very solid. We are able to get prior authorizations as long as they have the proper coding, and we've been able to show that the reimbursement is really consistent between the codes that have been educated. So we're kind of getting a lot of that behind us. The MACs have really become a little bit stable.

There's a couple that require a modifier, but even using a -52 modifier has not been problematic in the field. So coding has really kind of settled down now, and I think it's going to stay that way, especially because the commercial payers and Medicare, they know the new code is approved. They know that by mid-year, they need to start preparing-

Jon Block
Analyst, Stifel

to move

Tim Herbert
CEO, Inspire Medical

their system to go to the new code that will take effect January 1st, 2028. I think the coding aspect of it, I think, has really kind of settled down and stabilized.

Jon Block
Analyst, Stifel

And should remain that way until you start talking to these centers in, I don't know, July or August of next year saying-

Tim Herbert
CEO, Inspire Medical

To start wrapping up

Jon Block
Analyst, Stifel

Here's where you got to go to the new code starting Jan 1 of 2028.

Tim Herbert
CEO, Inspire Medical

Correct.

Jon Block
Analyst, Stifel

Okay. How about new facilities? If I rewind the clock three or four years ago, or even more, when I thought about Inspire's growth algo, it was driving utilization at existing centers, but then you would give us a new facility number.

How many additional facilities you were signing up. So you would get a contribution from a new store.

Tim Herbert
CEO, Inspire Medical

Correct.

Jon Block
Analyst, Stifel

I am guessing that was probably pretty difficult over the past 9 to 12 months with reimbursement in flux, to go to these facilities and say, "Hey, sign up and make this part of your hospital," when there was a lot of difficulty billing. So, if that is settled down, are you back on your front foot in terms of signing up new facilities and having that contribute to top-line growth?

Tim Herbert
CEO, Inspire Medical

Sure. I think that it is a little bit of a relative scale too. We have a much larger presence out in the field, so when we open sites, while we may not open to the bolus that we used to in the times that you are referring to, we were pretty consistent throughout the year at opening new territories. Even with this coding situation, we do put a focus on ambulatory surgical centers as well. But now that we are getting into the fourth quarter, we are starting to lean in. I do think with the OPPS last week, that is even further ability to accelerate the ramp-up. I think the key to it, when you look at our growth algorithm between increased utilization and contributions from new centers, with the number of centers that we have-

Jon Block
Analyst, Stifel

Sure

Tim Herbert
CEO, Inspire Medical

You just aren't able to really drive the new center growth as much. We still focus on increased utilization as a key part of our growth, but complement that with opening new centers. I would expect the fourth quarter, we're going to see a significantly higher number of centers open up as compared to the first three quarters of the year. That was still okay, but more nominal with what you saw in the past.

Jon Block
Analyst, Stifel

Okay. How has the retention been with the current facilities? In other words, did you get a lot of drops in facilities that stopped performing the procedure still to this day when reimbursement was in flux?

Tim Herbert
CEO, Inspire Medical

I think that we had a pause and a slowdown at centers, but we don't see a lot of drops. The reason is people are comfortable with the outcomes and they're comfortable with how the patients respond to the therapy. We want to re-excite those centers, but we want to make sure that they get back to a utilization that's worth their while and worth everybody's time. What I'm trying to say by that is centers that have the highest utilization have the best patient outcomes. It's because they're practiced. Everybody knows their role.

We really want to focus on centers that have the highest utilization, and if they can't get there, we might slow them down a little bit and say, "Let's kind of work on your center a little bit." They may or may not continue on the website per se, so we'll focus on fixing them to get their utilization back where we can really highlight those centers that can handle the patient flow and really show the strong patient outcomes.

Jon Block
Analyst, Stifel

Okay. Got about a little less than 10 minutes left. I want to hit on 2026 guidance and then 2027 guidance. For 2026, the revenue guidance is down 6% at the midpoint for the year. For 4Q 2026, the guidance reflects down 10% at the midpoint, but you are still up high teens, 3Q to 4Q, and that is really representative of what has gone on the past two years, the 3Q to 4Q. Maybe talk to us about what you are seeing in the field currently, and how are the prior authorizations with the commercial payers trending as you worked your way throughout 3Q and even the beginning of 4Q? That is an important component when we think about the fourth quarter.

Matt Osberg
CFO, Inspire Medical

Yeah. I mean, one of the most important things for us is driving improved utilization, right? As Tim talked about, as we came through the disruption the first half of the year, a big focus for us is to start building back that ability for the doctors and facilities to scale back up and get to their utilization. So that is something that we have been watching, something we have seen great trends in, well, improving trends in as we have gone through Q3, leading to our revenue improvement sequentially, and we expect another improvement in Q4 to be able to drive to the numbers that you mentioned. So seeing good trends there.

Prior authorizations, we are really focusing on continuing to go, continuing to try and reduce the time it takes to get someone through prior authorizations, because if we can accelerate that, we can accelerate the ability to get more implants in in the fourth quarter. So we are focused on that and really trying to operationalize that as we hit the fourth quarter, and we do expect kind of our typical seasonal improvement, but we want to see some of the underlying organics improve as we step through Q4.

Jon Block
Analyst, Stifel

And Tim, you used to always fight capacity a little bit in the fourth quarter, right? How do you feel on that front?

Tim Herbert
CEO, Inspire Medical

With the ASCs, you have more flexibility in scheduling. A key measure that we use inside is the time from a prior authorization to an implant, and in different facilities, that can be much shorter. As Matt mentioned, that gives us an ability to still perform prior authorizations even in December and get those cases done by the end of the month. With ASC, that gives us much more flexibility in scheduling and availability of ORs, and so we like the higher percentage there. Nonetheless, all of our territory managers are working with their facilities to make sure that they are reserving OR times later in the month.

We know our busiest implant week of the year is between Christmas and New Year's, because all the individuals, the patients with their high deductible insurance plans demand they got to get their procedure this week before their $3,000 high deductible, whatever it is, resets on January 1st. We all start doing implants on Saturdays, of course, and people, our team and the physicians and healthcare providers, they really start ramping up. They know the big push is going to be at the end of the year, and that's always very consistent.

Jon Block
Analyst, Stifel

Okay. Sorry, guys, if you have questions, sometimes I've got my head down, just throw up your hand. I do want to pivot to 2027 guidance, ask about the absolute, and then I want to make sure I hit on the cadence a little bit, because I think the street's a little off on 1Q. So you guided low single-digit revenue growth and implies $870 million-$875 million for 2027, roughly. Just talk to the dynamics that allow for the resumption of growth. I can think of a lot of variables, the sort of easy comps, Project Horizon, some of the $120 million that maybe comes back next year. But what went into your calculus when you're pointing to the resumption of growth in 2027?

Tim Herbert
CEO, Inspire Medical

Yeah, let me comment on this and then hand it over to Matt, just talk about some of the cadence that you referenced as well. I think the key is looking at where we're coming from. It's been a challenge as we kind of worked through this year to go to have an experience where we're having the high single digit down to get back to the growth. So we're excited to be able to commit back to the growth and start looking at setting that up as low single-digit growth. Again, it's all about patient outcomes and being able to help patients work through that process to get back to where we need to be, back in a growth situation, and then from there, keep leaning in even further. But if you want to comment a little bit on cadence too.

Matt Osberg
CFO, Inspire Medical

Yeah. One thing that has really kind of been very consistent for us, if you look back to 2025, 2024, 2023, and look at the amount of revenue that is done in each quarter relative to the full year's revenue, it has been very consistent. As we are trying to provide some early color on 2027 with low single digits, the way we are thinking about that is we expect to kind of return into that similar cadence. So that similar distribution of revenue of the full year into the quarter should be pretty consistent in our view right now.

Jon Block
Analyst, Stifel

I went back and I pulled some of that, because I think we had a little bit of this conversation after the earnings call, and you are usually around like 21% of revenue in 1Q.

Matt Osberg
CFO, Inspire Medical

Yep.

Jon Block
Analyst, Stifel

So 21% on your full year gets you to about $185-ish.

Matt Osberg
CFO, Inspire Medical

Yep

Jon Block
Analyst, Stifel

in 1Q, and street is closer to like $193, give or take. Okay.

Matt Osberg
CFO, Inspire Medical

And that's natural. That's where we are today, kind of-

Jon Block
Analyst, Stifel

Yep

Matt Osberg
CFO, Inspire Medical

moving back up, maybe a little still negative in Q1.

Jon Block
Analyst, Stifel

But then turning-

Matt Osberg
CFO, Inspire Medical

But then turning profitable at that point.

Yeah.

Jon Block
Analyst, Stifel

Okay. I'll hit on this one quickly, replacement opportunity.

Tim Herbert
CEO, Inspire Medical

Yeah.

Jon Block
Analyst, Stifel

I've been following you long enough to know about this one, right? What are we doing here? We're pulling the procedures from 10 years ago. We're putting some conversion rate on it. What we're doing is we're pulling it from 10 years ago, Tim, 75% conversion rate and an ASP on generator only of about $20,000. Just maybe your thoughts.

Tim Herbert
CEO, Inspire Medical

Yeah. I think that's a very similar way that we would think about it, right? I think there's a blend of where that is it exactly somebody from 10 years ago, or is it kind of a blend over a couple of years? But I think you're thinking about it the right way, and we're looking forward as we start to go back now 10 years and see how that revenue almost doubled every year, that we get more significant contribution from that replacement revenue in 2027, and then as we step in years beyond 2027.

Jon Block
Analyst, Stifel

Okay.

Tim Herbert
CEO, Inspire Medical

It's exciting that after all these years, for the first time, we're talking about replacements.

Jon Block
Analyst, Stifel

Yep.

Tim Herbert
CEO, Inspire Medical

It is going to just continue to build and add to everybody's models, and we are excited about the patients coming through and continuing on with their therapy. The patients who are coming through now have the old Inspire II unit, that they get replaced with an Inspire V, which is about a third of its size, yet still gets 11-year battery life. So, they get a significant technology improvement.

Jon Block
Analyst, Stifel

That is a good segue to the last topic, which at least I left you one minute for.

Tim Herbert
CEO, Inspire Medical

Okay.

Jon Block
Analyst, Stifel

When you say improvement, talk to us about innovation. You alluded to Inspire VI.

Tim Herbert
CEO, Inspire Medical

Yeah.

Jon Block
Analyst, Stifel

Somewhere in there, how does Inspire want to get at the CCC opportunity longer term?

Tim Herbert
CEO, Inspire Medical

Sure. I think that, let's jump to the path or the technical roadmap that we have. Inspire V really increased outcomes as we showed on that one chart, and it's because of the inspiratory overlap in our algorithms. What limits it today is people don't use the therapy all night, every night. CPAP's a great therapy, but people don't use CPAP to the level that they need to. Inspire VI is going to have sleep detection to it, and so when the patient falls asleep, the device will turn itself on, and we can take therapy adherence to the highest level, thereby taking outcomes even a step further. There's further developments down the road with Inspire VII and beyond that we'll get into at a later date. The digital tools are going to continue to evolve.

How we communicate with the patients, that once they come to a website and identify themselves as a potential patient, we know that if they're a qualified patient, that we can communicate, even texting with the patients to get them the information that they need. So when they see the ENT, they're coming in decision-ready. Finally, post-implant, we want to make it easier for the sleep physicians to be able to manage these patients, and one of the avenues that we're really focusing on is remote programming. So, the physicians can program from their office to the patient's home, and I think that's going to really make it a lot easier for the patients, and again, allow us to focus on what is our number one priority, is prioritizing patient outcomes.

It's been a long, tough year, and I give credit to the Inspire team, the whole field team, for their positive persistence to be able to overcome challenges, especially when you get these challenges with the reimbursement. The key with reimbursement is they're difficult problems to solve, but they do get solved, it just takes time. We're at the point now that we're transitioning to the corrective action side.

Jon Block
Analyst, Stifel

Yep.

Tim Herbert
CEO, Inspire Medical

We're seeing the improvements of reimbursement next year with a new code scheduled for the following year.

Jon Block
Analyst, Stifel

Fair enough.

Tim Herbert
CEO, Inspire Medical

Thank you for having us.

Jon Block
Analyst, Stifel

We will see you there. Thanks, Tim. Thanks, Matt. Appreciate it.

Tim Herbert
CEO, Inspire Medical

Thank you. Very good.